FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
Executive Summary
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
You may also be interested in...
Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow
Safety concerns over erythropoiesis-stimulating agents seem to extend to Affymax's peginesatide, and since it lacks an efficacy edges over these drugs in treating anemia due to chronic kidney disease, an approval basis is unclear.
Class-Wide Rx Safety Issues Are Focus Of FDA Guidance On New Label Change Powers
FDA is emphasizing a class-based approach to requiring safety-related drug labeling changes under the FDA Amendments Act.
Class-Wide Rx Safety Issues Are Focus Of FDA Guidance On New Label Change Powers
FDA is emphasizing a class-based approach to requiring safety-related drug labeling changes under the FDA Amendments Act.